行情

NBY

NBY

Novabay制药
AMEX

实时行情|Nasdaq Last Sale

0.6126
+0.0036
+0.59%
交易中 14:12 09/21 EDT
开盘
0.6100
昨收
0.6090
最高
0.6197
最低
0.6100
成交量
4.75万
成交额
--
52周最高
1.790
52周最低
0.5150
市值
2,753.23万
市盈率(TTM)
-3.0357
分时
5日
1月
3月
1年
5年
与面具相关的戏剧走得更高；纽约州州长 Hochul 表示受州监管的儿童保育设施需要戴口罩
-Reuters
Reuters · 6天前
英国卫生和社会保健大臣表示 B 计划包括在某些情况下合法强制戴面罩
- Reuters
Reuters · 09/14 11:49
NovaBay Pharmaceuticals 将出席 HC Wainwright 第 23 届年度全球投资大会
EMERYVILLE, Calif., September 08, 2021--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The company presentation wi...
Business Wire · 09/08 10:50
伊利诺伊州州长宣布全州范围内的室内口罩授权
-Bloomberg
Bloomberg · 08/26 15:24
简报-NovaBay Pharmaceuticals 将分销 Zcular 干眼症产品
reuters.com · 08/19 11:17
NovaBay Pharmaceuticals 将分销 Zeye 干眼症产品
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zocular dry eye products
Benzinga · 08/19 10:55
NovaBay Pharmaceuticals 将分销 Zcular® 干眼症产品
EMERYVILLE, Calif. & CYPRESS, Texas, August 19, 2021--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zo...
Business Wire · 08/19 10:50
纽约州副州长 Kathy Hochul 表示，学校儿童戴口罩是必要的安全措施
-CNN
CNN · 08/15 13:57
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解NBY最新的财务预测，通过NBY每股收益，每股净资产，每股现金流等数据分析Novabay制药近期的经营情况，然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

强力推荐

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测NBY价格均价为2.700，最高价位3.500，最低价为1.900。
EPS
机构持股
总机构数: 20
机构持股: 64.76万
持股比例: 1.44%
总股本: 4,494.34万
类型机构数股数
增持
3
38.36万
建仓
7
17.45万
减持
6
9.77万
平仓
2
1.24万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.37%
制药与医学研究
+0.72%
高管信息
Non-Executive Chairman/Independent Director
Paul Freiman
Chief Executive Officer/Chief Compliance Officer/General Counsel/Director/IR Contact Officer
Justin Hall
Chief Financial Officer/Treasurer
Andrew Jones
Director
Xinzhou Li
Director
Mijia Wu
Independent Director
Swan Sit
Independent Director
Yenyou Zheng
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
NBY 简况
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

微牛提供NovaBay Pharmaceuticals, Inc.(AMEX-NBY)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NBY股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NBY股票基本功能。